You are viewing an incomplete version of our website. Please click to reload the website as full version.

AML1-MTG8 antibody

Details for Product No. ABIN965546, Supplier: Login to see New
Request Want additional data for this product?

The Independent Validation Initiative strives to provide you with high quality data. Find out more

Immunohistochemistry (IHC)
Pubmed 10 references available
Supplier Login to see New
Catalog number from supplier Login to see New
Quantity 0.1 mg
Shipping to United States ( )
Availability Will be delivered in 5 to 7 Business Days
Immunogen Polyclonal antibody produced in rabbits immunizing with a synthetic peptide corresponding to C-terminal residues of human AML1-MTG8(acute myelogenous leukemia 1 translocation 1 protein isoform MTG8c)
Purification Purified by antigen-specific affinity chromatography.
Background AML1-MTG8(acute myelogenous leukemia 1 translocation 1 protein isoform MTG8c) is a putative zinc finger transcription factor and oncoprotein. In acute myeloid leukemia, especially in the M2 subtype, the t(8,21)(q22,q22) translocation is one of the most frequent karyotypic abnormalities. The translocation produces a chimeric gene made up of the 5'-region of the RUNX1 gene fused to the 3'-region of this gene. The chimeric protein is thought to associate with the nuclear corepressor/histone deacetylase complex to block hematopoietic differentiation. Several transcript variants encoding multiple isoforms have been found for this gene.
Application Notes ELISA, Western blotting: 1µg/ml for 2hrs.
Restrictions For Research Use only
Format Liquid
Buffer This antibody is stored in PBS, 50% glycerol
Preservative Sodium azide
Precaution of Use This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Storage -20 °C
Product cited in: Martinez, Drescher, Riehle et al.: "The oncogenic fusion protein RUNX1-CBFA2T1 supports proliferation and inhibits senescence in t(8;21)-positive leukaemic cells." in: BMC cancer, Vol. 4, pp. 44, 2004 (PubMed).

Background publications Liu, Shen, Huynh et al.: "Interplay of RUNX1/MTG8 and DNA methyltransferase 1 in acute myeloid leukemia." in: Cancer research, Vol. 65, Issue 4, pp. 1277-84, 2005 (PubMed).

Lindberg, Olsson, Persson et al.: "The Leukemia-associated ETO homologues are differently expressed during hematopoietic differentiation." in: Experimental hematology, Vol. 33, Issue 2, pp. 189-98, 2005 (PubMed).

Lausen, Cho, Liu et al.: "The nuclear receptor co-repressor (N-CoR) utilizes repression domains I and III for interaction and co-repression with ETO." in: The Journal of biological chemistry, Vol. 279, Issue 47, pp. 49281-8, 2004 (PubMed).

Zhang, Kalkum, Yamamura et al.: "E protein silencing by the leukemogenic AML1-ETO fusion protein." in: Science (New York, N.Y.), Vol. 305, Issue 5688, pp. 1286-9, 2004 (PubMed).

Lindberg, Olsson, Persson et al.: "Interactions between the leukaemia-associated ETO homologues of nuclear repressor proteins." in: European journal of haematology, Vol. 71, Issue 6, pp. 439-47, 2004 (PubMed).

Chevallier, Corcoran, Lennon et al.: "ETO protein of t(8;21) AML is a corepressor for Bcl-6 B-cell lymphoma oncoprotein." in: Blood, Vol. 103, Issue 4, pp. 1454-63, 2004 (PubMed).

McGhee, Bryan, Elliott et al.: "Gfi-1 attaches to the nuclear matrix, associates with ETO (MTG8) and histone deacetylase proteins, and represses transcription using a TSA-sensitive mechanism." in: Journal of cellular biochemistry, Vol. 89, Issue 5, pp. 1005-18, 2003 (PubMed).

Follows, Tagoh, Lefevre et al.: "Epigenetic consequences of AML1-ETO action at the human c-FMS locus." in: The EMBO journal, Vol. 22, Issue 11, pp. 2798-809, 2003 (PubMed).

Tonks, Pearn, Tonks et al.: "The AML1-ETO fusion gene promotes extensive self-renewal of human primary erythroid cells." in: Blood, Vol. 101, Issue 2, pp. 624-32, 2003 (PubMed).

Catalog No. ABIN965546
Plus shipping costs $45.00

Order hotline:

  • +1 877 302 8632
  • +1 888 205 9894 (TF)